title: [High-dose chemotherapy for metastatic breast cancer].
abstract: In ninety's breast cancer was first in Europe for the use of high-dose chemotherapy with autologous hematopoietic stem cell transplantation in solid tumors in adults. Some phase II trials of high-dose chemotherapy showed high response rates and prolonged progression free survival in selected metastastic breast cancer patients. Few large, powerful randomized phase III studies comparing this approach with conventional chemotherapy have been completed: some studies showed a better progression free survival in favor of high dose chemotherapy, but no statistically significant difference in overall survival was observed. Many variables inside high dose chemotherapy program need to be considered. The identification of subsets of breast cancer patients who can benefit from high-dose chemotherapy is essential: high-dose chemotherapy should be included in a global treatment strategy, evaluating the integration with innovative treatment modalities, with the aim of eradicating the minimal residual disease in breast cancer patients achieving complete response after high dose chemotherapy.
authors.affiliation: Unità Operativa Complessa di Oncologia Medica, Ospedale S. Eugenio, Roma, Italia. mlallepove@inwind.it
authors.forename: M
authors.initials: M
authors.lastname: Lalle
authors.forename: L
authors.initials: L
authors.lastname: De Rosa
authors.forename: A
authors.initials: A
authors.lastname: Perillo
authors.forename: G
authors.initials: G
authors.lastname: Scambia
authors.forename: M
authors.initials: M
authors.lastname: D'Aprile
authors.forename: M
authors.initials: M
authors.lastname: Antimi
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D016032:Randomized Controlled Trials as Topic
chemical_list: D000970:Antineoplastic Agents